News Releases

Year

Nov 18, 2019

UroGen to Present at November 2019 Investor Conferences

NEW YORK --(BUSINESS WIRE)--Nov. 18, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will participate in fireside chats at the following conferences in November: Stifel 2019

Nov 12, 2019

UroGen Pharma Reports Third Quarter 2019 Financial Results and Recent Corporate Developments

Completed Submission of New Drug Application (NDA) to U.S. FDA for UGN-101 in Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Exclusive Worldwide License Agreement with Agenus to Advance Treatment of High-Grade Urinary Tract Cancers in Combination with UGN-201 Conference Call and

Nov 11, 2019

UroGen Pharma Announces Exclusive License Agreement with Agenus Inc to Advance Treatment of Urinary Tract Cancers

UroGen to Develop and Commercialize Zalifrelimab (AGEN1884, anti-CTLA-4 antibody) with UGN-201 for High-Grade Non-Muscle Invasive Bladder Cancer NEW YORK --(BUSINESS WIRE)--Nov. 11, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address

Nov 06, 2019

UroGen Pharma to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

Conference Call and Webcast Scheduled for Tuesday, November 12, 2019 at 8:30 AM ET NEW YORK --(BUSINESS WIRE)--Nov. 6, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report third quarter 2019 financial results on Tuesday, November 12, 2019 , prior to the open of the market.

Sep 30, 2019

UroGen To Present at October 2019 Investor Conference

NEW YORK --(BUSINESS WIRE)--Sep. 30, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will present at the following conference in October: 2019 Cantor Global Healthcare

Sep 24, 2019

UroGen Investor Day Details Positive Clinical Updates, UGN-101 Launch Preparedness, and Pipeline Advances

UGN-101 and UGN-102 Demonstrate Positive Clinical Data in Low-Grade Upper Tract Urothelial Cancer (LG UTUC) and Low-Grade Non-Muscle Invasive Bladder Cancer (LG NMIBC) UGN-101 Final Data Modules for NDA Submission On-Track for Q4 2019 UGN-101 Plans for Launch Readiness by January 2020

Sep 24, 2019

UroGen Reports Positive Data from Two Important Studies: UGN-101 OLYMPUS Pivotal Trial in LG UTUC and UGN-102 Phase 2b OPTIMA II Trial in LG Bladder Cancer

UGN-101: Consistent Complete Response (CR) Rate of 59 Percent in Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC) Durability of Response Determined to be 89 Percent at Six Months and 84 Percent at 12 Months Rolling NDA Submission on Track for Q4 2019 with Planned Launch in

Sep 10, 2019

UroGen To Host Investor Day on September 24, 2019 Spotlighting Clinical Development Updates and UGN-101 Launch Readiness

Company to Also Participate in September Investor Conferences NEW YORK --(BUSINESS WIRE)--Sep. 10, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will host an Investor Day on

Sep 06, 2019

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK --(BUSINESS WIRE)--Sep. 6, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced the grants of inducement restricted stock units (“RSUs”) to 15 new employees in connection with their

Aug 09, 2019

UroGen Pharma Reports Second Quarter 2019 Financial Results and Recent Corporate Developments

UGN-101 Rolling NDA Submission on Track for Q4 2019 with Planned Launch in 1H 2020 Final Topline UGN-101 Phase 3 Data from OLYMPUS Trial to be Announced in Q3 2019 Company Investor Day Scheduled for September 24, 2019 Quarterly Conference Call and Webcast to be Held on Monday, August 12, 2019 at

Current page 1
Page 2
Page 3
Next page
Last page

Investors

Investors

News Releases

News Releases

Investors

Investors

Urogen - Investor Relations

News Releases

News Releases

Urogen - Tools

Follow us on